Compare OWLT & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OWLT | CERS |
|---|---|---|
| Founded | 2013 | 1991 |
| Country | United States | United States |
| Employees | 85 | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 318.6M | 276.0M |
| IPO Year | N/A | 1996 |
| Metric | OWLT | CERS |
|---|---|---|
| Price | $7.33 | $1.94 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | 175.9K | ★ 1.5M |
| Earning Date | 01-01-0001 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.27 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $51,326,000.00 |
| Revenue This Year | $37.02 | $20.00 |
| Revenue Next Year | $22.14 | $9.60 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 30.68 |
| 52 Week Low | $2.75 | $1.12 |
| 52 Week High | $16.94 | $2.96 |
| Indicator | OWLT | CERS |
|---|---|---|
| Relative Strength Index (RSI) | 24.09 | 36.67 |
| Support Level | N/A | $1.34 |
| Resistance Level | $9.63 | $2.26 |
| Average True Range (ATR) | 0.82 | 0.19 |
| MACD | -0.12 | -0.05 |
| Stochastic Oscillator | 4.77 | 8.13 |
Owlet Inc is engaged in providing a digital parenting platform that aims to give parents real-time data and insights to help parents feel more calm and confident. Its diversified portfolio of products includes Owlet Smart Sock, the first baby monitor to track an infant's oxygen levels, heart rate, and sleep trends; the Owlet Cam, which turns any smartphone into a baby monitor with high-definition clarity; the Owlet Monitor Duo, which offers the intelligence of the Owlet Smart Sock paired with the Owlet Cam; and Owlet Dream Lab, an interactive online program designed to be a parent's guide to building healthy sleep habits for their infants.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.